Welcome to the Week in Review.

TrumpRx Announced

Even in a crowded week of news, prescription drug pricing remained prominent with President Trump’s announcement of TrumpRx — a new government direct-to-consumer platform — alongside a deal with Pfizer to offer Medicaid prescriptions at most-favored-nation (MFN) prices. The rollout underscores that drug pricing is a top administration priority, but key questions remain about the program: Which drugs will be covered? Will patients see any savings? And who ultimately benefits? The program does cut out middlemen, but also allows pharma to continue setting prices at will. Pfizer’s prominent role in the announcement signals that drugmakers expect to come out ahead. The reality is clear: drug companies — not PBMs or pharmacies — dictate launch prices, and that’s the root cause of unaffordable medicines. While DTC programs may offer limited relief to some patients, only structural reforms like Medicare negotiation can rein in monopoly pricing power and deliver lasting affordability. P4AD patient advocate Sarah Wisniewski underscored that point on BBC World Business Report and with CBS, sharing her own struggles with high drug costs and what these announcements could mean for patients like her. — [White HouseBBCCBSPOLITCOInside Health PolicyThe HillBloombergSTAT NewsAxiosPink SheetEndpoints NewsFierce PharmaWashington ExaminerBarron’s

ORPHAN Re-score Anticipated Soon

The Congressional Budget Office (CBO) is still working on a re-score of the ORPHAN Cures Act, but we’re expecting a number well beyond the original $5 billion estimate, which failed to include a range of blockbuster drugs, including Keytruda. Championed by the pharmaceutical industry, ORPHAN exempts many high-cost drugs from negotiation, keeping prices artificially higher even longer. Lawmakers should learn from this mistake and reject pharma’s next push for carveouts through bills like EPIC and MINI. — [KFFCongressCongress]

New Profile on P4AD Patient Advocates

The Epoch Times published a profile of three P4AD patient advocates — Sarah, Beth, and Sanie — who traveled from across the country to D.C to share their firsthand experiences with the crushing cost of prescription drugs. During their meetings with lawmakers they pressed Congress to rein in patent abuse and protect Medicare negotiation. Their stories are powerful: spending thousands each month on treatments, rationing doses of life-saving medication, and navigating endless hurdles just to maintain coverage. Sadly, these experiences are all too common in our broken drug pricing system. With one in three Americans struggling to afford their prescription drugs, and nine in ten demanding action on the issue, the message to Congress couldn’t be clearer: it’s time to act. You can read the full profile here. — [Epoch Times]

In Case You Missed It

P4AD Executive Director Merith Basey will be joining GW Law’s Inflation Reduction Act event next Friday for a panel on the bill’s most urgent questions, threats, and challenges around drug pricing.

Patient Advocate Spotlight: Sarah Wisniewsi

Condition: Multiple Sclerosis (MS)
Drug: Kesimpta, and a range of immunotherapy drugs

In her words: ““No one can afford to pay for this drug when the monthly out of pocket cost is $8,736!”

“Even though my disease remains active, I am still able to work at a good job and remain a productive, tax paying member of society, but that will not be the case if I have to shoulder the cost of the Kesimpta on top of everything else. I don’t want to have to go on disability just so I can survive and hopefully get my medication paid for.”

Subscribe to the WEEK IN REVIEW here.